Form DEFA14A ClearPoint Neuro, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
Preliminary Proxy Statement |
|
|
o |
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
o |
Definitive Proxy Statement |
|
|
x |
Definitive Additional Materials |
|
|
o |
Soliciting Material Pursuant to Rule 14a-12 |
CLEARPOINT NEURO, INC.
(Name of Registrant as Specified in Its Charter)
Not Applicable
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x |
No fee required. |
|
|
o |
Fee paid previously with preliminary materials: |
|
|
o |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lion Copper Corp. to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 13th
- Osteogenesis Imperfecta Market Osteogenesis Imperfectased to Grow from USD 30 Million in 2023 to USD 500 Million by 2034 as First Targeted Therapies Near Approval
- Advanced Renal Cell Carcinoma Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2034 – DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
